Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis

Journal of Neuropathology and Experimental Neurology

Volumn 61, Issue 1, 2002, Pages 23-32

  Wujek, J R ^a   Bjartmar, C ^a   Richer, E ^a   Ransohoff, R M ^a   Yu, M ^a   Tuohy, V K ^a   Trapp, B D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Axonal loss; Experimental autoimmune encephalomyelitis; Inflammation; Multiple sclerosis

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISABILITY; DISEASE SEVERITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD;

EID: 0036136532     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/61.1.23     Document Type: Article

References (51)

1. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis
2. Demyelinating diseases - New pathological insights, new therapeutic targets
3. Axonal damage in acute multiple sclerosis lesions
4. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease
5. Axonal transection in the lesions of multiple sclerosis
6. Neurological disability correlates with spinal cord axonal loss and reduce N-acetyl aspartate in chronic multiple sclerosis patients
7. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression
8. A spinal cord MRI study of benign and secondary progressive multiple sclerosis
9. Animal models for autoimmune demyelinating disorders of the nervous system
10. New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice
11. Genetic analysis of experimental allergic encephalomyelitis in mice
12. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis
13. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis
14. Creation of a model for multiple sclerosis in Callithrix jacchus marmosets
15. Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: A correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus)
16. The rapid production of acute disseminated encephaloymyelitis in rhesus monkeys by injection of brain tissue with adjuvants
17. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions
18. Chronic relapsing experimental allergic encephalomyelitis: Identification and dynamics of T and B cells within the central nervous system
19. In situ characterization of mononuclear cell infiltrates in lesions of multiple sclerosis
20. Multiple sclerosis: Distribution of T-cell subsets within active chronic lesions
21. Identification and quantitation of T lymphocyte subsets found in the spinal cord of the Lewis rat during acute experimental allergic encephalomyelitis
22. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions
23. The role of CD45 and CD45-associated molecules in T cell activation
24. The longstanding MS lesion. A quantitative MRI and electron microscopic study
25. Neurodegeneration in multiple sclerosis: Relationship to neurological disability
26. Magnetic resonance spectroscopy: Imaging axonal damage in MS
27. Immunohistochemical analysis of the rat central nervous system during experimental allergic encephalomyelitis, with special reference to Ia-positive cells with dendritic morphology experimental autoimmune disease of the peripheral nervous system
28. The immunopathology of chronic experimental allergic encephalomyelitis induced in rabbits with bovine proteolipid protein
29. Experimental autoimmune encephalomyelitis: The antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system
30. Compression injury of mammalian spinal cord in vitro and the dynamics of action potential conduction failure
31. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
32. The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK
33. Nerve conduction block by nitric oxide that is mediated by the axonal environment
34. Preliminary studies of cytokine-induced functional effects on the visual pathways in the rabbit
35. Electrophysiological analysis of factors involved in the primary demyelinating diseases: The rabbit eye model system
36. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
37. Digitized image analysis reveals diffuse abnormalities in normal-appearing white matter during acute experimental autoimmune encephalomyelitis
38. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis
39. Spinal cord axonal loss in multiple sclerosis: A post-mortem study
40. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis
41. Axonal changes in chronic demyelinated cervical spinal cord plaques
42. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis
43. Spinal cord MRI using multi-array coils and fast spin echo: II. Findings in multiple sclerosis
44. A comparison of the pathology of primary and secondary progressive multiple sclerosis
45. Multiple sclerosis
46. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis
47. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history
48. Relapsing-remitting multiple sclerosis: Sequential enhanced MR imaging vs clinical findings in determining disease activity
49. Relapses and progression of disability in multiple sclerosis
50. Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis
51. Progress in determining the causes and treatment of multiple sclerosis